Eliot Charles, MiroBio executive chairman

Ox­ford spin­out nabs al­most $100M in new cash to test PD-1 in au­toim­mune dis­eases and hunt for a CEO

Af­ter about 15 years in an Ox­ford lab and three more years in the up­start world fol­low­ing a 2019 spin­out, Miro­Bio is ready to en­ter UK clin­i­cal tri­als and, en route to the clin­ic, the biotech has picked up $97 mil­lion in Se­ries B funds.

The £80 mil­lion fi­nanc­ing round kicked off in earnest last Sep­tem­ber and in­cludes a transat­lantic con­sor­tium — led by Medicxi — ready to bankroll that first clin­i­cal tri­al, be­gin­ning “im­mi­nent­ly,” as well as the de­but study of a sec­ond pro­gram there­after, ex­ec­u­tive chair Eliot Charles, an SR One ven­ture part­ner, told End­points News.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.